Incremental costs and utilities for palivizumab versus no prophylaxis using the IRST to identify moderate- and high-risk 32–35wGA infants.
收藏数据链接：
官方服务：
资源简介：
Incremental costs and utilities for palivizumab versus no prophylaxis using the IRST to identify moderate- and high-risk 32–35wGA infants.
创建时间：
2023-08-10
